Composition for allergy prevention, atopic dermatitis alleviation or skin regeneration, containing, as active ingredient, undecane or undecanal

A technology of atopic dermatitis and active ingredients, applied in the direction of allergic diseases, active ingredients of aldehydes, skin care preparations, etc., can solve problems such as hand tremors, hair loss, deterioration, and safety of side effects have not been ensured, and reduce inflammation The effect of the reaction

Pending Publication Date: 2021-09-24
植物感觉株式会社
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, tacrolimus may cause side effects such as deterioration of kidney function, tremors, and hair loss, and pimecrolimus may cause serious side effects such as skin cancer and lymphoma as well as acne and burning
Steroids are appropriate for exacerbations and topical immunomodulators are appropriate for mild atopy and maintenance therapy, but safety against side effects has not been established, so alternative complementary products are urgently needed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for allergy prevention, atopic dermatitis alleviation or skin regeneration, containing, as active ingredient, undecane or undecanal
  • Composition for allergy prevention, atopic dermatitis alleviation or skin regeneration, containing, as active ingredient, undecane or undecanal
  • Composition for allergy prevention, atopic dermatitis alleviation or skin regeneration, containing, as active ingredient, undecane or undecanal

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0100] Example 1: Evaluation of secretion and expression of inflammation-related cytokines after decanogenesis of hypertrophyletal cells and keratinum

[0101] 1-1. Experimental method

[0102] 1) Mermatology

[0103] Mermatic cells (rat basinosycellular leukemia cell line, RBL-2H3) were purchased from ATCC (National Virginia Manasas) and used. DMEM (Gibco BRL) (Gibco BRL) (Gibco BRL) (Gibco BRL) (Gibco BRL) (Gibco BRL) (Gibco BRL) (Gibco BRL) (Gibco BRL) (Gibco BRL) (Gibco BRL) , US) culture cells in the medium. By at 37 ° C, 5% CO 2 Culture was cultured under conditions to test cells. The fat cells were suspended in DMEM containing 10% FBS, then assigned to 1 × 10 in 6-well plates (Corning, US). 6 Cell / ml number of cells.

[0104] Then, it was sensitized with anti-DNP (dinitrobenzene) -iGe (30 ng / ml), and in the incubator at 37 ° C, 5% CO 2 The incubation was cultured for 24 hours. After washing with PBS (phosphate buffered saline), 4 hours were treated with DNP-HSA (dinitro...

Embodiment 2

[0116] Example 2: Evaluation of the secretion and expression of inflammation related cytokines after umethral aldehyde infendal cells and keratin forming cells

[0117] 2-1. Experimental Method

[0118] 1) Mermatology

[0119] Mermatic cells (rat basinosycellular leukemia cell line, RBL-2H3) were purchased from ATCC (National Virginia Manasas) and used. DMEM (Gibco BRL) (Gibco BRL) (Gibco BRL) (Gibco BRL) (Gibco BRL) (Gibco BRL) (Gibco BRL) (Gibco BRL) (Gibco BRL) , US) culture cells in the medium. By at 37 ° C, 5% CO 2 Culture was cultured under conditions to test cells. Mermatocytes were suspended in DMEM containing 10% FBS and then assigned to 1 × 106 cells / mL cells in 6-well plates (Corning, US).

[0120] Then, it was sensitized with anti-DNP (dinitrobenzene) -iGe (30 ng / ml), and in the incubator at 37 ° C, 5% CO 2 The incubation was cultured for 24 hours. After washing with PBS (phosphate buffered saline), 4 hours were treated with DNP-HSA (dinitropyr-serum albumin; 10 μg...

preparation Embodiment 1

[0131] [Preparation Example 1] Preparation of the pharmaceutical composition

[0132] Preparation of Powder

[0133] 20mg of decanoalk or eleven aldehyde

[0134] 100mg lactose hydrate

[0135] 10mg talc

[0136] The above components were mixed and mounted in an invasive cloth to prepare a powder.

[0137] Preparation of Tablets

[0138] 10mg of uldell or eleven aldehyde

[0139] 100mg corn starch

[0140] 100mg lactose hydrate

[0141] 2mg magnesium stearate

[0142] After mixing the above ingredient, a tablet is prepared by a method according to a conventional prepared tablet.

[0143] Preparation of Capsules

[0144] 10mg of uldell or eleven aldehyde

[0145] 3MG microcrystalline cellulose

[0146] 14.8mg lactose hydrate

[0147] 0.2mg magnesium stearate

[0148] After mixing the above ingredient, the capsule is prepared in the gelatin capsule according to the conventional preparation capsule.

[0149] Preparation of Injection

[0150] 10mg of uldell or eleven aldehyde

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
boiling pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a composition for allergy prevention, atopic dermatitis alleviation or skin regeneration, containing, as an active ingredient, undecane or undecanal and, more specifically, to a composition for preventing or treating allergic disease or atopic dermatitis and a composition for healing skin wound or promoting skin regeneration, both of which contain, as an active ingredient, at least one selected from a group consisting of undecane, undecanal or pharmaceutically acceptable salts thereof.

Description

Technical field [0001] This application claims priority to Korean Patent Application No. 10-2019-0003549 of January 10, 2019 submitted, which is incorporated herein by reference in its entirety. [0002] The present disclosure relates to an allergic disease, or for preventing or treating Laid-containing or undecanal undecane as an active ingredient for prevention of allergy, atopic dermatitis or alleviate skin regenerating compositions, and more particularly, relates to atopic dermatitis compositions and healing of skin wounds or for promoting skin regeneration composition comprising both selected undecane, or a pharmaceutically acceptable salt thereof undecanal as an active ingredient at least one. Background technique [0003] Atopic from ancient Greek "atopia", which means "strange, unusual." Cooke and Coca for the first time in 1923 will induce genetic tendency specific immune antibody response against allergens known as "atopy." Atopic worldwide has been growing steadily, an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/01A61K31/11A61K9/00A61P37/08A61P17/00A61P17/02A61K8/31A61K8/33A61Q19/00
CPCA61P17/00A61P17/02A61P37/08A23L33/16A61Q19/08A61K8/31A61K8/33A61K31/01A61K31/11A23L33/10A61Q19/00A61Q13/00A23V2002/00A23V2200/318A23V2200/304
Inventor 朴太瑄
Owner 植物感觉株式会社
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap